Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

    Get Diamond plan for FREE

    logo

    SIGA Technologies, Inc. (SIGA)

    Price:

    6.64 USD

    ( - -0.16 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    SIGA
    Name
    SIGA Technologies, Inc.
    Industry
    Drug Manufacturers - Specialty & Generic
    Sector
    Healthcare
    Price
    6.640
    Market Cap
    475.499M
    Enterprise value
    273.377M
    Currency
    USD
    Ceo
    Diem Nguyen
    Full Time Employees
    46
    Website
    Ipo Date
    1997-09-10
    City
    New York City
    Address
    31 East 62nd Street

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    HUTCHMED (China) Limited

    VALUE SCORE:

    9

    Symbol
    HCM
    Market Cap
    2.738B
    Industry
    Drug Manufacturers - Specialty & Generic
    Sector
    Healthcare

    2nd position

    Neurocrine Biosciences, Inc.

    VALUE SCORE:

    9

    Symbol
    NBIX
    Market Cap
    13.163B
    Industry
    Drug Manufacturers - Specialty & Generic
    Sector
    Healthcare

    The best

    Amphastar Pharmaceuticals, Inc.

    VALUE SCORE:

    10

    Symbol
    AMPH
    Market Cap
    1.285B
    Industry
    Drug Manufacturers - Specialty & Generic
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    6.385
    P/S
    2.761
    P/B
    2.337
    Debt/Equity
    0.004
    EV/FCF
    2.618
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    1.768
    Earnings yield
    0.157
    Debt/assets
    0.004
    FUNDAMENTALS
    Net debt/ebidta
    -1.814
    Interest coverage
    0
    Research And Developement To Revenue
    0.106
    Intangile to total assets
    0.004
    Capex to operating cash flow
    0.003
    Capex to revenue
    0.002
    Capex to depreciation
    0.608
    Return on tangible assets
    0.323
    Debt to market cap
    0.002
    Piotroski Score
    5.000
    FUNDAMENTALS
    PEG
    -0.684
    P/CF
    4.174
    P/FCF
    4.187
    RoA %
    32.154
    RoIC %
    33.455
    Gross Profit Margin %
    76.287
    Quick Ratio
    7.235
    Current Ratio
    9.168
    Net Profit Margin %
    43.233
    Net-Net
    2.370
    FUNDAMENTALS PER SHARE
    FCF per share
    1.624
    Revenue per share
    2.406
    Net income per share
    1.040
    Operating cash flow per share
    1.629
    Free cash flow per share
    1.624
    Cash per share
    2.401
    Book value per share
    2.842
    Tangible book value per share
    2.829
    Shareholders equity per share
    2.842
    Interest debt per share
    0.013
    TECHNICAL
    52 weeks high
    9.620
    52 weeks low
    4.950
    Current trading session High
    6.840
    Current trading session Low
    6.585
    DIVIDEND
    Dividend yield
    9.04%
    Payout ratio
    57.8%
    Years of div. Increase
    1.000
    Years of div.
    4.000
    Q-shift
    Dividend per share
    0.600
    SIMILAR COMPANIES
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -6.637
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    34.040
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Diagnostics & Research
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -15.741
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    7.717
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -6.235
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -13.778
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    518.889
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    5.512
    logo

    Country
    CA
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -5.915
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -9.344
    DESCRIPTION

    SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.

    NEWS
    https://images.financialmodelingprep.com/news/stock-traders-buy-large-volume-of-call-options-on-20260205.png
    Stock Traders Buy Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)

    defenseworld.net

    2026-02-05 01:42:46

    Siga Technologies Inc. (NASDAQ: SIGA - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock investors acquired 1,200 call options on the company. This represents an increase of 1,438% compared to the average daily volume of 78 call options. Siga Technologies Price Performance NASDAQ: SIGA opened at $6.73 on Thursday. The

    https://images.financialmodelingprep.com/news/traders-purchase-large-volume-of-call-options-on-siga-technologies-20251225.png
    Traders Purchase Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)

    defenseworld.net

    2025-12-25 03:32:54

    Siga Technologies Inc. (NASDAQ: SIGA - Get Free Report) was the target of unusually large options trading on Wednesday. Traders bought 1,200 call options on the company. This is an increase of approximately 1,438% compared to the typical volume of 78 call options. Wall Street Analyst Weigh In A number of analysts recently commented on the

    https://images.financialmodelingprep.com/news/takeda-pharmaceutical-nysetak-vs-siga-technologies-nasdaqsiga-headtohead-review-20251215.png
    Takeda Pharmaceutical (NYSE:TAK) vs. Siga Technologies (NASDAQ:SIGA) Head-To-Head Review

    defenseworld.net

    2025-12-15 01:46:56

    Siga Technologies (NASDAQ: SIGA - Get Free Report) and Takeda Pharmaceutical (NYSE: TAK - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk. Analyst Recommendations This is a summary of current

    https://images.financialmodelingprep.com/news/siga-technologies-sees-unusually-large-options-volume-nasdaqsiga-20251127.png
    Siga Technologies Sees Unusually Large Options Volume (NASDAQ:SIGA)

    defenseworld.net

    2025-11-27 02:12:50

    Siga Technologies Inc. (NASDAQ: SIGA - Get Free Report) saw some unusual options trading on Wednesday. Traders purchased 1,200 call options on the stock. This represents an increase of approximately 1,438% compared to the typical daily volume of 78 call options. Institutional Inflows and Outflows Institutional investors and hedge funds have recently added to or reduced

    https://images.financialmodelingprep.com/news/siga-technologies-inc-siga-shares-sold-by-aviva-plc-20251115.png
    Siga Technologies Inc. $SIGA Shares Sold by Aviva PLC

    defenseworld.net

    2025-11-15 04:08:45

    Aviva PLC trimmed its holdings in Siga Technologies Inc. (NASDAQ: SIGA) by 51.7% in the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 51,144 shares of the company's stock after selling 54,717 shares during the period. Aviva PLC owned approximately 0.07% of Siga Technologies worth $333,000 at

    https://images.financialmodelingprep.com/news/siga-technologies-inc-siga-q3-2025-earnings-call-transcript-20251107.jpg
    SIGA Technologies, Inc. (SIGA) Q3 2025 Earnings Call Transcript

    seekingalpha.com

    2025-11-07 06:56:11

    SIGA Technologies, Inc. ( SIGA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Diem Nguyen - CEO & Director Daniel Luckshire - Executive VP, CFO & Secretary Conference Call Participants Jyoti Prakash - Edison Investment Research Limited Presentation Operator Welcome to the SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements.

    https://images.financialmodelingprep.com/news/siga-reports-financial-results-for-three-and-nine-months-20251106.jpg
    SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025

    globenewswire.com

    2025-11-06 16:01:00

    NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2025. “We continue to advance SIGA's key priorities while generating $86 million in product revenues and $33 million in pre-tax operating income for the first nine months of 2025," stated Diem Nguyen, Chief Executive Officer.

    https://images.financialmodelingprep.com/news/siga-to-host-business-update-call-on-november-6-2025-20251030.png
    SIGA to Host Business Update Call on November 6, 2025 Following Release of Third-Quarter 2025 Results

    globenewswire.com

    2025-10-30 07:30:00

    NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 6, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

    https://images.financialmodelingprep.com/news/saskatchewan-indian-gaming-authority-siga-modernizes-pointofsale-and-inventory-20250911.jpg
    Saskatchewan Indian Gaming Authority (SIGA) Modernizes Point-of-Sale and Inventory Operations Across Seven Casinos with Agilysys Solutions

    businesswire.com

    2025-09-11 08:05:00

    ALPHARETTA, Ga.--(BUSINESS WIRE)--Agilysys, Inc. (Nasdaq: AGYS), a leading global provider of hospitality software and services, today announced that the Saskatchewan Indian Gaming Authority (SIGA) has chosen Agilysys InfoGenesis POS and Agilysys Eatec inventory and procurement solutions for enterprise-wide use across all seven of its casino properties in Saskatchewan. This milestone represents a major advancement in SIGA's strategy to modernize its operations at scale. This modernization initi.

    https://images.financialmodelingprep.com/news/7-big-yields-from-the-beatup-healthcare-sector-20250901.jpg
    7 Big Yields From The Beat-Up Healthcare Sector

    forbes.com

    2025-09-01 10:52:04

    Healthcare stocks haven't moved since the April lows. As contrarian investors, this neglect piques our interest.

    https://images.financialmodelingprep.com/news/siga-technologies-still-bullish-but-worth-trimming-ahead-of-20250820.jpg
    SIGA Technologies: Still Bullish, But Worth Trimming Ahead Of BARDA News

    seekingalpha.com

    2025-08-20 02:00:05

    SIGA's investment thesis is overwhelmingly tied to the renewal of the BARDA contract, which remains highly uncertain due to political and budgetary risks. Recent revenue growth and a strong balance sheet are positives, but the company faces label risk in the EU and heavy reliance on U.S. government funding. Potential catalysts include TPOXX label expansion for post-exposure prophylaxis and a new BARDA contract, while EU label changes and U.S. defunding are key risks.

    https://images.financialmodelingprep.com/news/siga-technologies-inc-siga-q2-2025-earnings-call-transcript-20250806.jpg
    SIGA Technologies, Inc. (SIGA) Q2 2025 Earnings Call Transcript

    seekingalpha.com

    2025-08-06 01:59:43

    SIGA Technologies, Inc. (NASDAQ:SIGA ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Daniel J. Luckshire - Executive VP, CFO & Secretary Diem Nguyen - CEO & Director Conference Call Participants Jyoti Prakash - Edison Investment Research Limited Operator Welcome to the SIGA Business Update Call.

    https://images.financialmodelingprep.com/news/siga-reports-financial-results-for-three-and-six-months-20250805.jpg
    SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025

    globenewswire.com

    2025-08-05 16:01:00

    NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and six months ended June 30, 2025.

    https://images.financialmodelingprep.com/news/3-healthcare-stocks-paying-the-highest-dividends-of-2025-20250805.jpg
    3 Healthcare Stocks Paying the Highest Dividends of 2025

    fool.com

    2025-08-05 05:50:00

    The healthcare sector has long been a favorite for income investors -- and for good reason. Many healthcare stocks offer attractive dividend yields.

    https://images.financialmodelingprep.com/news/siga-to-host-business-update-call-on-august-5-20250729.jpg
    SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

    globenewswire.com

    2025-07-29 07:30:00

    NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.